As real-world data such as patient-reported outcomes (PROs) gain importance in the clinical setting for MS disease monitoring, at least one previous study reported the correlation between baseline sNfL and PROs relevant to physical function.28,29 To our knowledge, no study has examined the association between blood multi-protein biomarker profile (beyond NfL or GFAP alone) and patient-reported MS disability. The gene discussed is GFAP; the disease is myeloid sarcoma.